AstraZeneca weathers patent expiry storm
October 27, 2011Sales and Marketing AstraZeneca, AstraZenecca, q3 2011
AstraZeneca saw its revenue decline in the third quarter due to an onslaught of patent expiries, but still saw its …
Lessons from the world of iPad detailing
October 27, 2011Medical Communications
This is an article for those who have chosen the iPad as an e-detailing tool. It’s not an argument on …
Alex Butler leaves Janssen to set up Social Moon pharma network
October 27, 2011Medical Communications Alex Bytler, Jansse, Janssen, comms
Social media guru Alex Butler has left Janssen to establish Social Moon, a digital-only marketing and comms agency for the …
Lansley talks tough on failing hospitals
October 27, 2011Medical Communications Andrew Lansley, NHS reforms
The health secretary Andrew Lansley says he will intervene to remove management boards of hospitals which can’t clear debts or …
Biogen’s MS drug hits phase III targets
October 27, 2011Sales and Marketing BG-12, Biogen, MS
Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial. BG-12 (dimethyl fumarate) tablets …
GSK sees strong Q3 after battling headwinds
October 27, 2011Business Services, Sales and Marketing GSK, GSK. Q3, Q3
GlaxoSmithKline has posted a set of healthy figures for the third quarter, underlying its return to growth after a tough …
Mepact wins NICE backing
October 26, 2011Research and Development, Sales and Marketing Mepact, NICE
NICE has recommended Takeda’s bone cancer drug Mepact after the firm offered a discount for the treatment. The watchdog’s final …
Reforms raise conflicts of interest, say GPs
October 25, 2011Sales and Marketing BMA, NHS, NHS reforms
Two-thirds of doctors believe that the government’s health reforms will create conflicts of interests in their jobs and undermine their …
Novartis to cut 2,000 jobs
October 25, 2011Manufacturing and Production, Research and Development
Novartis will cut around 2,000 jobs is the US and Switzerland as part of additional cost saving measures. The positions …
David Meeker appointed as chief executive of Genzyme
October 25, 2011Research and Development, Sales and Marketing Genzyme, Sanofi
Sanofi has appointed David Meeker as chief executive of its new biotech acquisition Genzyme. He will report to Christopher Viehbacher, …
Pharma manufacturing news in brief
October 25, 2011Manufacturing and Production pharma manufacturing news
Patheon wins a new contract from Boehringer Ingelheim, Ferring buys a UK plant, plus updates from InvaGen, CrossJect and contract …
New venture a ‘game-changer’ for pharma
October 25, 2011Research and Development Sir Christopher Evans, drug development
Sir Christopher Evans is looking to create a new venture that aims to improve on the drug development productivity of …
GSK warned by FDA about Worthing plant
October 25, 2011Manufacturing and Production
The US FDA has issued a warning letter to GlaxoSmithKline, noting that its manufacturing plant in Worthing, UK, failed to …
Sanofi’s Lemtrada beats Rebif in MS study
October 25, 2011Research and Development, Sales and Marketing Lemtrada, Sanofi
Sanofi’s investigational multiple sclerosis drug Lemtrada has beaten Rebif in a late-stage trial. The Phase III results show that 78% …
Flamel secures production contract for GSK heart failure drug
October 25, 2011Manufacturing and Production Coreg CR, Flamel, GSK, manufacturing
France’s Flamel Technologies has won a long-term contract from GlaxoSmithKline focusing on the production of the drugmaker’s Coreg CR heart …
Risk Based Inspections for good pharmacovigilance practice
October 24, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Recently in the UK there has been a move towards risk-based inspection programmes. The scope, frequency and depth of MHRA …
#fakedrugs: Scammers using Twitter to peddle fake medicines
October 24, 2011Medical Communications Digital Pharma blog, Twitter
Scammers are exploiting Twitter to entice people into buying fake medicines, according to a new report. The report, published by …
Does drug development deliver on its promises?
October 24, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, R&D
I am always guided by the motto of the Royal Society, ‘Nullius in Verba’. This means, with typical Latin brevity: …
TranslateMedia listed in Deloitte UK Technology Fast 50 for 2011
October 24, 2011The Deloitte UK Technology Fast 50 was founded in 1998, and remains one of Britain’s foremost technology programs. The program …
Merck to invest $1billion in Singapore R&D and manufacturing
October 24, 2011Manufacturing and Production, Research and Development
Singapore has reinforced its position as a major pharmaceutical hub for the Asia-Pacific region with the news that Merck is …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
